氨酸/氨酸激酶36诱导的表皮细胞-介质细胞过渡促进前列腺癌中多塞塔塞尔耐药性
Tao He1, Nan-Xing Li1, Zhao-Jun Pan2
1Department of Emergency Surgery, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology; The Third Affiliated Hospital of Guangzhou Medical University, 63 DuoBao Road, Guangzhou, Guangdong, 510150, People's Republic of China.
Scientific reports
|January 6, 2024
概括
氨酸/氨酸激酶36 (STK36) 在前列腺癌 (PCa) 中被上调,促进细胞生长和多塞素耐药性. STK36的激活可能会驱动上皮质-介质细胞过渡 (EMT),为PCa.提供潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 前列腺癌 (PCa) 仍然是一个重大的健康问题,而多塞素耐药性构成了主要的临床挑战.
- 了解导致多塞素耐药性的分子机制对于开发有效的治疗策略至关重要.
研究的目的:
- 调查氨酸/氨酸激酶36 (STK36) 在前列腺癌中多塞素耐药性的发展中的作用和机制.
- 探索STK36作为一种潜在的治疗点,以克服PCa.中的多塞素耐药性.
主要方法:
- 在PCa组织中分析STK36表达和与临床病理特征的相关性.
- 在体外研究涉及STK36在PCa细胞系中的过度表达和沉默 (DU-145,PC-3).
- 评估细胞增殖 (CCK8),入侵 (Transwell),迁移 (伤口划伤试验),亡 (TUNEL试验) 和上皮-介质细胞过渡 (EMT) 标志物 (西斑).
主要成果:
- 在PCa组织中,STK36表达显著上调,与晚期和降低整体存活率相关.
- 过度表达STK36促进了PCa细胞的增殖,入侵和迁移,同时也产生了对多塞素的耐药性.
- STK36上调导致E-Cadherin减少和Vimentin表达增加,表明EMT的激活. Knockdown 的 STK36 逆转了这些效应.
结论:
- STK36的上调加速PCa的进展和多塞素耐药性,可能是通过EMT的激活.
- 在前列腺癌治疗中,STK36代表了一种有前途的治疗点,可以提高多塞的疗效.
相关概念视频
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


